Eli Lilly, Novo Nordisk Shares Dip as Pfizer Ramps Up Diabetes Drug Competition
Eli Lilly, Novo Nordisk Shares Dip as Pfizer Ramps Up Diabetes Drug Competition
Shares of $Eli Lilly and Co (LLY.US)$ and $Novo-Nordisk A/S (NVO.US)$ finished lower on Thursday, perhaps influenced by competitive developments and regulatory updates in the pharmaceutical sector.
股票$禮來 (LLY.US)$和頁面。$諾和諾德 (NVO.US)$週四收盤走低，有可能受到藥品板塊中競爭局勢以及監管更新的影響。
What Happened: $Pfizer (PFE.US)$ has selected its preferred once-daily modified release formulation for danuglipron, a GLP-1 receptor agonist. This decision by Pfizer intensifies competition in the diabetes treatment market. Both JPMorgan and Berenberg have maintained Buy ratings on Eli Lilly, raising their price targets to $1000.
發生了什麼：$輝瑞 (PFE.US)$輝瑞已選擇其首選的每日一次緩釋劑型danuglipron，它是一種GLP-1受體激動劑。這個決定加劇了糖尿病治療市場的競爭。摩根大通和貝恩伯格都維持了對伊利莎白公司的買入評級，並將其目標價升至1000美元。
Meanwhile, Novo Nordisk has received a Complete Response Letter (CRL) from the FDA regarding its once-weekly basal insulin icodec. The FDA's requests related to manufacturing processes and indications for type 1 diabetes will delay potential approval, contributing to the stock's decline.
與此同時，諾和諾德收到了FDA關於其一週一次的基礎胰島素icodec的完整反應信(CRL)。FDA的要求涉及製造過程和1型糖尿病適應症，這將延遲潛在的批准，導致該股下跌。
The pharmaceutical sector's volatility today may be reflecting ongoing scrutiny over drug pricing practices, notably highlighted by Sen. Bernie Sanders (I-VT) targeting high prices of Novo Nordisk's drugs, Ozempic and Wegovy.
藥品板塊的波動可能反映了對藥品定價做法的持續審查，值得注意的是，參議員伯尼·桑德斯（I-VT）對諾和諾德的藥品Ozempic和Wegovy的高價進行了針對性的批評。
LLY and NVO Price Action: Eli Lilly shares were down by 0.61% at $934.14 and Novo Nordisk shares were down by 2.08% at $139.79 on Thursday, according to Benzinga Pro.
根據Benzinga Pro的數據顯示，週四Eli Lilly的股票下跌了0.61%，收於934.14美元，諾和諾德的股票下跌了2.08%，收於139.79美元。